Certara Services Archives

On-Demand Webinar

Payment Pressures in U.S. Specialty: Status quo and outlook for future financing

To allow for the optimal positioning of your product, portfolio, or company, it is critical…

CertaraSeptember 15, 2020

Case Study

Reimbursement and Launch Planning

CertaraJune 22, 2020

On-Demand Webinar

The Rare Disease Drug Dilemma: Great Value, High Price, Limited Access?

This webinar will explain how pricing has evolved for the rare disease drug market and…

CertaraFebruary 19, 2020

Blog

Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development

Model-based Meta-analysis is a framework to compare drugs used to treat diabetic peripheral neuropathy, post-herpetic…

CertaraDecember 19, 2019

Blog

ICER’s Unsupported Drug Price Increase Report: An Analysis

We analyze the drug-price watchdog, ICER’s (Institute for Clinical and Economic Review) “Report on Unsupported…

CertaraOctober 24, 2019

On-Demand Webinar

Innovative Solutions for Fast-Tracking Drugs for Rare Diseases

This webinar discussed which pharmaceutical payer strategies work and which don't in our rapidly changing…

CertaraAugust 10, 2019

Brochure

Evidence and Access Overview

Discover Certara’s holistic approach to market access.

CertaraMay 21, 2019

On-Demand Webinar

Advanced Analytics Using RWD Mitigates Risks in AD Drug Development & Reimbursement

This webinar explained how advanced analytics using real-world data can mitigate challenges in Alzheimer’s disease…

CertaraMay 13, 2019

Blog

Trends for Market Access, HEOR, and Real World Evidence

This blog reviews trends for using health economics and outcomes research and real-world evidence to…

CertaraMay 10, 2019

Blog

Real World Evidence Marches Forward in Drug Development

The end of 2018 ushered in a flurry of new regulatory guidance and sponsor enthusiasm…

CertaraMarch 20, 2019

Certara Services

Payment Pressures in U.S. Specialty: Status quo and outlook for future financing

Reimbursement and Launch Planning

The Rare Disease Drug Dilemma: Great Value, High Price, Limited Access?

Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development

ICER’s Unsupported Drug Price Increase Report: An Analysis

Innovative Solutions for Fast-Tracking Drugs for Rare Diseases

Evidence and Access Overview

Advanced Analytics Using RWD Mitigates Risks in AD Drug Development & Reimbursement

Trends for Market Access, HEOR, and Real World Evidence

Real World Evidence Marches Forward in Drug Development

Newsletter sign up

Quick links

Solutions

Contact